AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02700360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
Study NCT04277884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: Oral administration 2×250 mg capsules bid
Study NCT04277884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration 2 capsules bid
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 3
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
Study NCT01682265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretta procedure
Study NCT01682265 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: No radiofrequency delivered
Study NCT00521157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Go Medical Naltrexone implants
Description: Naltrexone implants 3.2 g (double of 1,6 g)
Study NCT02866513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.
Study NCT03983967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: Activated T lymphocyte
Study NCT02807272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral tablet
Study NCT00511173 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Warfarin Dose based on pharmacogenetics
Description: Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
Study NCT06079749 — intervention group
Intervention type: PROCEDURE
Intervention: Simultaneous BTKA
Description: Simultaneous BTKA
Study NCT06079749 — intervention group
Intervention type: PROCEDURE
Intervention: Staged BTKA
Description: Staged BTKA
Study NCT03427151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPP-201101
Description: 200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen Tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Celecoxib Tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Description: Celecoxib Tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine nerve block (injection)
Study NCT01727856 — intervention group
Intervention type: DEVICE
Intervention: Rehabilitation Measurement Tool
Description: The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
Study NCT02912312 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RNI
Study NCT02912312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02912312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02912312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02912312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02912312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02912312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02912312 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard RNI
Study NCT03212014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSVT-BIG
Description: LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
Study NCT03212014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POWER
Description: Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
Study NCT03212014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: traditional exercise models in currently clinical use
Study NCT03927859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a mail letter, a phone call and a phone call plus mailed letter
Description: All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Ropivicaine nerve block (injection)
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: ketorolac injection
Study NCT00938665 — intervention group
Intervention type: DEVICE
Intervention: COGNISION™ System
Description: 30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
Study NCT04617119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT device
Description: 10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
Study NCT04617119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: daily
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Injectable Product
Description: Acetaminophen injection
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Injectable Solution
Description: Morphine Patient Controlled Analgesia
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hydrocodone bitartrate and acetaminophen
Description: Norco tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: morphine injection
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone Hydrochloride
Description: oxycodone hydrochloride tablet
Study NCT03586934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: meloxicam tablet
Study NCT02756533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring of daily parameters recorded by NIV
Description: Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours.
Study NCT02756533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
Study NCT00047697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil HCl
Description: Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
Study NCT04617119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: daily
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIQ865A bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIQ865A bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ865A bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIQ865B bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIQ865B bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study NCT00047697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo used in placed of Donepezil HCL
Study NCT03698253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
Study NCT03698253 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA6)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
Study NCT03698253 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
Study NCT03698253 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA7/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
Study NCT04524377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.~The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain.
Study NCT01934790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
Study NCT03482089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoprostatectomy
Description: Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ865B bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluent for LIQ865
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent for LIQ865
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
Study NCT02982889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine hydrochoride
Description: single subcutaneous injection
Study NCT01945047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
Study NCT01945047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
Study NCT01581515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element everolimus eluting coronary stent
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
Study NCT01581515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime everolimus eluting coronary stent
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
Study NCT03166501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanicemine
Description: Three 60 min parenteral infusions over a 5 day period
Study NCT03166501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three 60 min parenteral infusions over a 5 day period
Study NCT00707057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg Extended-Release Tablets
Description: Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Study NCT00707057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Study NCT04485078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure pain threshold
Description: The PPT assessments of spine will be performed over the spinous process and 2 cm right and left side of the corresponding spinous process. The regional PPT scores will be composed from sum of all PPT values for related segments at spine. The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
Study NCT04485078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Temporal summation
Description: TS will be evaluated over the trapezius muscle, sacroiliac joints, C7, T6, and L3 levels at spine with manuel algometer. TS scores will be calculated for each spine level as the sum of three values which measured over the spinous process and 2 cm right and left side of corresponding level. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
Study NCT04485078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conditioned pain modulation
Description: First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 70C water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
Study NCT04485078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Central Sensitization Inventory
Description: Standardized questionnaire to determine the level of central sensitization
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Bath Ankylosing Spondylitis Disease Activity Index
Description: Standardized questionnaire to determine the level of disease activity in AxSpa patients
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Ankylosing Spondylitis Quality of Life
Description: Standardized questionnaire to investigate the quality of life in AxSpa patients
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Istanbul Low Back Pain Disability Index
Description: Standardized questionnaire to investigate the disability
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Beck Depression Inventory
Description: Standardized questionnaire to investigate the depression
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Fatigue Severity Scale
Description: Standardized questionnaire to investigate the fatigue
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Index
Description: Standardized questionnaire to investigate the sleep quality and disturbance
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Fibromyalgia Rapid Screening Tool
Description: Standardized questionnaire to detect fibromyalgia
Study NCT04485078 — intervention group
Intervention type: OTHER
Intervention: Visual analogue scale
Description: global pain score on a 0 to 10
Study NCT01302418 — intervention group
Intervention type: DEVICE
Intervention: artus Influenza A/B RT-PCR Test
Description: The investigational assay, used for detecting the presence of Influenza A/B.
Study NCT03482089 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiotherapy
Description: Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
Study NCT00802347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I5NP
Description: Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg
Study NCT00802347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg
Study NCT01697800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Study NCT01697800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04214366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion irradiation
Description: 22 x 3 Gy(RBE) Carbon Ions
Study NCT04214366 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bimodal irradiation
Description: 25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
Study NCT03630159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Gene modified autologous T cells
Study NCT03630159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti PD-1
Study NCT01030016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Description: 25 mg/day, twice a day for 6 weeks
Study NCT00848900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity
Description: Adding 1 hour outdoor time into school curricula
Study NCT01164150 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 45 Gy/25 fractions
Description: Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy